Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × HR+/HER2- Breast Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 392 Neoplasms 320 Breast Neoplasms 227 Colorectal Neoplasms 210 Melanoma 183 Neoplasm Metastasis 180 Multiple Myeloma 169 Leukemia, Myeloid, Acute 168 Pancreatic Neoplasms 161 Ovarian Neoplasms 160 Recurrence 151 Prostatic Neoplasms 136 Lymphoma, Non-Hodgkin 124 Stomach Neoplasms 118 Squamous Cell Carcinoma of Head and Neck 112 Lymphoma 108 Lung Neoplasms 108 Carcinoma, Hepatocellular 102 Carcinoma, Renal Cell 92 Leukemia, Lymphocytic, Chronic, B-Cell 91 Advanced Solid Tumor 87 Glioblastoma 86 Triple Negative Breast Neoplasms 85 Leukemia 85 Head and Neck Neoplasms 77 Lymphoma, Large B-Cell, Diffuse 76 Small Cell Lung Carcinoma 71 Myelodysplastic Syndromes 69 Endometrial Neoplasms 69 Advanced Solid Tumors 67

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡